Vermont at a glance
| Adults with obesity (CDC) | 29.1% (2025) |
|---|---|
| Medicaid pays for GLP-1s for obesity | No (KFF, Jan 2026) |
| Medicare GLP-1 Bridge | $50 copay for eligible Part D members, Jul 1, 2026 – Dec 31, 2027 |
| Physician licensing | Vermont Board of Medical Practice |
| Pharmacy licensing | Vermont Board of Pharmacy |
| Main metro areas | Burlington metro |
In short, the CDC puts adult obesity in Vermont at 29.1% for 2025, 42nd among the 47 states it reported that year. Vermont Medicaid did not pay for GLP-1s prescribed for obesity in KFF’s January 2026 survey; diabetes coverage is a separate benefit.
Insurance and public coverage in Vermont
Medicaid. Vermont Medicaid did not pay for GLP-1s prescribed for obesity in KFF’s January 2026 survey; diabetes coverage is a separate benefit.
Medicare. Medicare still cannot pay for drugs used only for weight loss under Part D, but the Medicare GLP-1 Bridge is a separate CMS program: from July 1, 2026 to December 31, 2027, eligible Part D members in Vermont pay $50 a month for Wegovy (pen or pill), Foundayo or the Zepbound KwikPen after prior authorization. The BALANCE model’s Part D arm will not start in 2027. Open enrollment runs October 15 to December 7, 2026.
Self-pay prices for Vermont residents
None of the programs we track charges Vermont a different price. These figures were read on the sellers’ own pages:
| Program | Product | Self-pay price | Read (2026) |
|---|---|---|---|
| NexLife (our #1) | Compounded semaglutide | $119/mo on a 12-month plan charged monthly; $139 month to month; no membership | Oct 14 |
| Collective | Compounded semaglutide | $59/mo plus a $199 yearly membership (about $76/mo) | Oct 14 |
| Wegovy pill (NovoCare) | Brand, FDA-approved | $149, $199 or $299 a month by dose | Oct 14 |
| Wegovy pen (NovoCare) | Brand, FDA-approved | $349 a month ($199 for the first two fills for new patients through Dec 31, 2026) | Oct 14 |
Every program with its billing basis and read date is on the compounded GLP-1 price comparison; the cheapest options are on cheapest compounded semaglutide online.
Checking the prescriber and pharmacy
A telehealth clinician who prescribes to you in Vermont needs a license Vermont recognizes. Physicians answer to the Vermont Board of Medical Practice; you can also search any physician on DocInfo.org. The pharmacy named on your vial label should be licensed by, or hold a nonresident permit from, the Vermont Board of Pharmacy. Our pharmacy profiles summarise FDA records for common compounders, and the 503A vs 503B guide explains the two license types.
Shipments go by mail across Vermont, including the Burlington metro.
Questions people in Vermont ask
Does Medicaid in Vermont pay for Wegovy for weight loss?
Vermont Medicaid did not pay for GLP-1s prescribed for obesity in KFF’s January 2026 survey; diabetes coverage is a separate benefit. Wegovy prescribed to lower heart risk is handled under different rules.
Can someone on Medicare in Vermont get Wegovy for $50 a month?
Possibly. Since July 1, 2026, the Medicare GLP-1 Bridge has let eligible Part D members anywhere in the U.S., including Vermont, fill Wegovy, Foundayo or the Zepbound KwikPen for a $50 monthly copay. It runs through December 31, 2027, uses BMI-based criteria and needs prior authorization; open enrollment runs October 15 to December 7, 2026.
What does semaglutide cost in Vermont without insurance?
Prices are national, so Vermont pays the same as other states. On October 14, 2026: compounded semaglutide $119 a month at NexLife on a 12-month plan charged monthly, or $59 plus a $199 yearly membership at Collective; brand Wegovy $149–$299 (pill) or $349 (pen) through NovoCare.
How can I check that an online prescriber is licensed in Vermont?
Look the clinician up on the Vermont Board of Medical Practice website or on DocInfo.org. Nurse practitioners in Vermont are licensed separately, usually by the board of nursing.
Is compounded semaglutide allowed in Vermont?
Yes, within federal limits. A pharmacy licensed by, or permitted to ship into, Vermont may compound it for you on an individual prescription, but compounded semaglutide is not FDA-approved and FDA has warned sellers who market copies or salt forms. Check the pharmacy with the Vermont Board of Pharmacy.
How many adults in Vermont have obesity?
The CDC puts adult obesity in Vermont at 29.1% for 2025, 42nd among the 47 states it reported that year. Wegovy is approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition.
Neighbouring states
New Hampshire, Massachusetts, New York. See all state guides, the provider comparison or our NexLife review.
Sources
Informational only, not medical advice. Compounded semaglutide is not FDA-approved and is not the same product as Wegovy® or Ozempic® (trademarks of Novo Nordisk).